|
Abstract To analyze the value of ultrasonography combined with the levels of serum carcino-embryonic antigen (CEA) and cytokerantin 19-fragment (Cyfra21-1) for differentiating benign or malignant of ovarian unilocular tumors serum. Methods: From January 2019 to December 2020, 185 patients with unilocular cystic and nonhomogeneous mass of ovary were selected as the research subjects, and these patients were examined by ultrasonography, and were detected of serum CEA and Cyfra21-1. Based on the pathological results as the gold standard, the values of ultrasonography combined with the levels of serum CEA and Cyfra21-1 for differentiating benign or malignant of ovarian unilocular tumors were analyzed. Results: The levels of serum CEA and C yfra21- 1 of the patients with benign of ovarian unilocular tumors were significantly higher than those of the patients with benign of ovarian unilocular tumors (P<0.001). The coincidence rate of the results by ultrasonography combined with the levels of serum CEA and CyFRA21-1 for diagnosing malignant of ovarian unilocular tumors and the pathological diagnosis was 94.6%. The Kappa value, the sensitivity, the specificity, the positive predictive value, and the negative predictive value of the ultrasonography combined with the levels of serum CEA, CyFRA21-1 for diagnosing malignant of ovarian unilocular tumors were 94.6%, 0.88, 92.3%, 95.8%, 92.3%, and 95.8%, respectively, which were significantly higher than those of ultrasonography, serum CEA level, or serum C yfra21-1 level alone (P<0.05). There were no significant differences in the sensitivity, the specificity, the positive predictive value, and the negative predictive value for diagnosing malignant of ovarian unilocular tumors among ultrasonography, serum CEA level, and serum Cyfra21-1 level (P>0.05). The receiver operation characteristic curve showed that ultrasonography combined with the levels of serum CEA and Cyfra21-1 had better differentiation efficacy for benign or malignant ovarian unilocular tumors, while the efficacy of ultrasonography, the serum CEA level, or the serum Cyfra21 level alone for differentiation of benign or malignant ovarian unilocular tumors was common. For the ovarian tumors with diameter <5cm and ≥5cm, the sensitivity and the specificity of ultrasonography combined with the levels of serum CEA and Cyfra21-1 for differentiating benign or malignant ovarian unilocular tumors were significantly higher than those of ultrasonography, the serum CEA level, or the serum Cyfra21 level alone (P<0.05). For the ovarian tumors with diameter <5cm, the sensitivity and the specificity of the serum CEA and CyFRA21-1 levels for differentiating malignant tumors were significantly higher than those of ultrasonography (P<0.05). For the ovarian tumors with diameter ≥5cm, there were no significant differences in the sensitivity and the specificity of the identification of the benign or malignant ovarian tumors among the serum CEA level, the serum Cyfra21-1 level, and ultrasonography (P<0.05). Conclusion: Differentiation efficacy for benign or malignant ovarian unilocular tumors of ultrasound combined with the serum CEA and Cyfra21-1 levels is better than that of ultrasonography, the serum CEA level, or the serum Cyfra21 level alone, especially for the tumors with shorter diameter has higher differentiation efficacy.
|
|
|
|
|
|
